Clinical Trial Design

• While significant advances have been made in treating many types of tumors, the treatment of locally advanced, unresectable or metastatic pancreatic cancer remains challenging, with survival measured in weeks and months.^{6, 7}
• Tarceva (erlotinib) plus gemcitabine is the first combination among numerous agents tested since 1996 to demonstrate statistically significant improvement in survival vs gemcitabine alone in patients with advanced pancreatic cancer.^{6, 8}

Indication and Usage

Tarceva in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

• Please see full prescribing information

• 1. Tarceva® (erlotinib) full prescribing information,OSI Pharmaceuticals,Inc., 2009.
• 6. Burris HA III, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
• 7. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049-1057.
• 8. FDA Center for Drug Evaluation and Research fact book 1997. Food and Drug Administration Web site. Available at: http://www.fda.gov/cder/reports/cderfact.pdf. Accessed August 29, 2005.